Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors
Cancer immunology, immunotherapy/Cancer immunology and immunotherapy